The Importance of Patient-reported Outcomes in Clinical Trials and Strategies for Future Optimization

Overview

Journal Patient Relat Outcome Meas

Specialty Health Services

Date 2018 Nov 23

PMID 30464666

Citations 216

Authors

Rebecca Mercieca-Bebber

Madeleine T King

Melanie J Calvert

Martin R Stockler

Michael Friedlander

Affiliations

Soon will be listed here.

Abstract

Patient-reported outcomes (PROs) can be included in clinical trials as primary or secondary endpoints and are increasingly recognized by regulators, clinicians, and patients as valuable tools to collect patient-centered data. PROs provide unique information on the impact of a medical condition and its treatment from the patient's perspective; therefore, PROs can be included in clinical trials to ensure the impact of a trial intervention is comprehensively assessed. This review first discusses examples of how PRO endpoints have added value to clinical trial interpretation. Second, it describes the problems with current practices in designing, implementing, and reporting PRO studies, and how these problems may be addressed by complying with guidance for protocol development, selecting appropriate PRO measures to match clinically motivated PRO hypotheses, minimizing the rates of avoidable missing PRO data, analyzing and interpreting PRO data, and transparently reporting PRO findings.

Citing Articles

New evidence for content validity of the German version of the Acute Cystitis Symptom Score: cognitive interview study among patients and experts.

Nestler S, Apfelbacher C, Ozkan E, Naber K, Piontek K World J Urol. 2025; 43(1):86.

PMID: 40085224 DOI: 10.1007/s00345-024-05406-2.

Metabolic crossroads: unravelling immune cell dynamics in gastrointestinal cancer drug resistance.

Suri C, Pande B, Suhasini Sahithi L, Swarnkar S, Khelkar T, Verma H Cancer Drug Resist. 2025; 8:7.

PMID: 40051496 PMC: 11883236. DOI: 10.20517/cdr.2024.164.

Impact of non-surgical periodontal therapy on self-perceived halitosis, and the senses of smell and taste: a prospective clinical study.

Tastan Eroglu Z, Kalender M, Ucan Yarkac F, Babayigit O, Ozkan Sen D BMC Oral Health. 2025; 25(1):321.

PMID: 40022178 PMC: 11869614. DOI: 10.1186/s12903-025-05702-2.

Using Virtual Reality to Improve Outcomes Related to Quality of Life Among Older Adults With Serious Illnesses: Systematic Review of Randomized Controlled Trials.

Maheta B, Kraft A, Interrante N, Fereydooni S, Bailenson J, Beams B J Med Internet Res. 2025; 27:e54452.

PMID: 40009834 PMC: 11904368. DOI: 10.2196/54452.

Defining a 'cells to society' research framework for appendiceal tumours.

Holowatyj A, Overman M, Votanopoulos K, Lowy A, Wagner P, Washington M Nat Rev Cancer. 2025; .

PMID: 39979656 DOI: 10.1038/s41568-024-00788-2.

References

Fielding S, Fayers P, Ramsay C . Analysing randomised controlled trials with missing data: choice of approach affects conclusions. Contemp Clin Trials. 2012; 33(3):461-9. DOI: 10.1016/j.cct.2011.12.002. View

Mack D, Wilson P, Santos E, Brooks K . Standards of reporting: the use of CONSORT PRO and CERT in individuals living with osteoporosis. Osteoporos Int. 2017; 29(2):305-313. DOI: 10.1007/s00198-017-4249-z. View

Osoba D, Tannock I, Ernst D, Neville A . Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol. 1999; 17(6):1654-63. DOI: 10.1200/JCO.1999.17.6.1654. View

Post W, Buijs C, Stolk R, de Vries E, le Cessie S . The analysis of longitudinal quality of life measures with informative drop-out: a pattern mixture approach. Qual Life Res. 2009; 19(1):137-48. PMC: 2804788. DOI: 10.1007/s11136-009-9564-1. View

Mercieca-Bebber R, Perreca A, King M, Macann A, Whale K, Soldati S . Patient-reported outcomes in head and neck and thyroid cancer randomised controlled trials: A systematic review of completeness of reporting and impact on interpretation. Eur J Cancer. 2016; 56:144-161. DOI: 10.1016/j.ejca.2015.12.025. View

Snyder C, Watson M, Jackson J, Cella D, Halyard M . Patient-reported outcome instrument selection: designing a measurement strategy. Value Health. 2007; 10 Suppl 2:S76-85. DOI: 10.1111/j.1524-4733.2007.00270.x. View

Luckett T, King M . Choosing patient-reported outcome measures for cancer clinical research--practical principles and an algorithm to assist non-specialist researchers. Eur J Cancer. 2010; 46(18):3149-57. DOI: 10.1016/j.ejca.2010.08.002. View

Joly F, Vardy J, Pintilie M, Tannock I . Quality of life and/or symptom control in randomized clinical trials for patients with advanced cancer. Ann Oncol. 2007; 18(12):1935-42. DOI: 10.1093/annonc/mdm121. View

Kyte D, Duffy H, Fletcher B, Gheorghe A, Mercieca-Bebber R, King M . Systematic evaluation of the patient-reported outcome (PRO) content of clinical trial protocols. PLoS One. 2014; 9(10):e110229. PMC: 4198237. DOI: 10.1371/journal.pone.0110229. View

10.

Kluetz P, Slagle A, Papadopoulos E, Johnson L, Donoghue M, Kwitkowski V . Focusing on Core Patient-Reported Outcomes in Cancer Clinical Trials: Symptomatic Adverse Events, Physical Function, and Disease-Related Symptoms. Clin Cancer Res. 2016; 22(7):1553-8. DOI: 10.1158/1078-0432.CCR-15-2035. View

11.

Friedlander M, Trimble E, Tinker A, Alberts D, Avall-Lundqvist E, Brady M . Clinical trials in recurrent ovarian cancer. Int J Gynecol Cancer. 2011; 21(4):771-5. DOI: 10.1097/IGC.0b013e31821bb8aa. View

12.

Stuart G, Kitchener H, Bacon M, duBois A, Friedlander M, Ledermann J . 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer. 2011; 21(4):750-5. DOI: 10.1097/IGC.0b013e31821b2568. View

13.

Bottomley A, Pe M, Sloan J, Basch E, Bonnetain F, Calvert M . Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards. Lancet Oncol. 2016; 17(11):e510-e514. DOI: 10.1016/S1470-2045(16)30510-1. View

14.

Palmer M, Mercieca-Bebber R, King M, Calvert M, Richardson H, Brundage M . A systematic review and development of a classification framework for factors associated with missing patient-reported outcome data. Clin Trials. 2017; 15(1):95-106. DOI: 10.1177/1740774517741113. View

15.

Schnipper L, Davidson N, Wollins D, Blayney D, Dicker A, Ganz P . Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received. J Clin Oncol. 2016; 34(24):2925-34. DOI: 10.1200/JCO.2016.68.2518. View

16.

Fielding S, MacLennan G, Cook J, Ramsay C . A review of RCTs in four medical journals to assess the use of imputation to overcome missing data in quality of life outcomes. Trials. 2008; 9:51. PMC: 3225816. DOI: 10.1186/1745-6215-9-51. View

17.

Calvert M, Kyte D, Mercieca-Bebber R, Slade A, King M, Hunn A . Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension. JAMA. 2018; 319(5):483-494. DOI: 10.1001/jama.2017.21903. View

18.

Glasziou P, Altman D, Bossuyt P, Boutron I, Clarke M, Julious S . Reducing waste from incomplete or unusable reports of biomedical research. Lancet. 2014; 383(9913):267-76. DOI: 10.1016/S0140-6736(13)62228-X. View

19.

Larkin M, Lorenzi G, Bayless M, Cleary P, Barnie A, Golden E . Evolution of the study coordinator role: the 28-year experience in Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC). Clin Trials. 2012; 9(4):418-25. PMC: 3815574. DOI: 10.1177/1740774512449532. View

20.

Revicki D, Osoba D, Fairclough D, Barofsky I, BERZON R, Leidy N . Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. Qual Life Res. 2001; 9(8):887-900. DOI: 10.1023/a:1008996223999. View